Fig. 5

Pooled estimates of the network meta-analysis. (A) Pooled odds ratios (95% credible intervals) for objective response rate. (B) Pooled odds ratios (95% credible intervals) for adverse events of grade 3 or higher. Data in each cell are hazard or odds ratios (95% credible intervals) for the comparison of row-defining treatment versus column-defining treatment. Odds ratios more than 1 favour row-defining treatment. Significant results are in bold. Ale 300 mg, alectinib 300 mg; Ale 600 mg, alectinib 600 mg; Bri, brigatinib; Cer, ceritinib; Chemo, chemotherapy; Cri, crizotinib; Ens, ensartini; Lor, lorlatinib; Grade ≥ 3 AEs, adverse events of grade 3 or higher